About Tandem Diabetes
Tandem Diabetes is a publicly listed company based in San Diego (United States) founded in 2008. Developer of devices for continuous glucose monitoring and manual insulin delivery. Tandem Diabetes has raised $100.73 million across 6 funding rounds from investors including CRG. The company has 2,650 employees. Tandem Diabetes has completed 4 acquisitions, including Advanced Microfluidics, Amf Medica and Capillary Biomedical. Its website tandemdiabetes.com draws about 385 thousand monthly visits. Its focus areas include Life Sciences, Diabetes, Medical Devices and Therapeutic Devices. Its competitors include Modular Medical, Asante Solutions and Disetronic; 1 of its 3 listed competitors has raised funding.
Company details
Tandem Diabetes is a developer of devices for continuous glucose monitoring and manual insulin delivery. It develops insulin pumps other products and services that bring innovation, convenience style to diabetes management. The first product, the t: slim Insulin Pump, features a sleek, modern design, intuitive touch-screen interface, and a rechargeable lithium-polymer battery. The company claims that this makes them closer to producing a fully automated closed-loop automated insulin delivery device that will not require human intervention to release insulin.
- Headquarters San Diego, United States
- Employees 2,650
- Stage Public
- SectorsHealthcare
- Website category Health · Health Conditions and Concerns
- Website tandemdiabetes.com
- Social LinkedIn X Facebook
- Legal Name Tandem Diabetes Care, Inc.
- Annual Revenue$1.02 B (USD)7.99as on Dec 31, 2025
- Net Profit-$204.71 M (USD)-113.18as on Dec 31, 2025
- EBITDA-$59.84 M (USD)27.48as on Dec 31, 2025
- Total Equity Funding$100.73M (USD)
in 6 rounds
- Latest Funding Round$287.5M (USD), Post-IPO
May 2020
- Investors
- Employee Count2,650
- Investments & AcquisitionsAdvanced Microfluidics
& 3 more
Apps and channels of Tandem Diabetes
Tandem Diabetes publishes 2 mobile apps with over 100K+ downloads.
Funding Insights of Tandem Diabetes
Tandem Diabetes has successfully raised a total of $100.73M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $287.5 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $100.73M
- Total Rounds 6
- Last Round Post-IPO — $287.5M
- First Round $52.34M
(Jan 2010)
- Investors Count 1
All 6 funding rounds of Tandem Diabetes with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2020 | $287.5M | Post-IPO | – | – | – |
| Jan 2018 | $40M | Post-IPO | – | – | – |
| Jan 2016 | $80M | Debt – Conventional | – | – | |
| Sep 2012 | $36.39M | Series D | – | – | – |
| Aug 2011 | $12M | Series C | – | – | – |
| Jan 2010 | $52.34M | Series C | – | – | – |
1 investors in total: 1 institutional.
Investors in Tandem Diabetes
Tandem Diabetes has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include CRG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
CRG is recognized as a premier healthcare investment partner. | crglp.com | Houston, United States |
Investor details for Tandem Diabetes
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Tandem Diabetes
251 people are tracked at Tandem Diabetes (79 in leadership, 7 in board & advisors, 165 in team); the tracked headcount is 2,650.
| Name | Role | Group |
|---|---|---|
Dave Nuttall | VP, Finance | Leadership |
John F. Sheridan | President & CEO | Leadership |
Peter Rossiter | VP, Information Technology | Leadership |
Julia Kensick | VP, Quality | Leadership |
Susan Morrison | EVP & Chief Administrative Officer | Leadership |
Michael Michaud | VP, Research & Development | Leadership |
Arun Kumar | VP, Supply Chain | Leadership |
Ross Sylvia | VP, Marketing | Leadership |
Scott Kloos | Sr Director, Pump Manufacturing/test Engineering | Leadership |
Jeff Brown | VP, Program Management | Leadership |
Christina Sun | VP, Corporate Controller | Leadership |
Jessica Paul | Director, Learning And Talent Management | Leadership |
Virginia Lu | Director, Product Management / Advanced Technology Development | Leadership |
Elizabeth Ankeny | Sr. Director, Human Resources | Leadership |
Robert Perez | Director, Cyber Security Operations | Leadership |
Jeff Henrichs | Vice President Of IT Platforms | Leadership |
Michael Gaudi | Head Of IT Operations/services, PMO And Governance | Leadership |
Joseph Schneider | Vice President Of Commercial Operations | Leadership |
Kim Richardson | VP Privacy, Chief Privacy Officer - Tandem Diabetes Care | Leadership |
Leigh Vosseller | EVP & CFO | Leadership |
231 more people are available in the full profile.
Complete people profiles for Tandem Diabetes
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Tandem Diabetes
Tandem Diabetes is a publicly listed company on the NASDAQ with ticker symbol TNDM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Nov 2013
- Listed onNASDAQ: TNDM
- Listed entityTandem Diabetes Care, Inc.
- Exchange sectorHealth technology
- ISINUS8753722037
- Share price$16.65 (+1.22% on the day) · 2026-10-13
- Market capitalisation$1.16B
- EPS (diluted, trailing year)$-0.93
- Volume (last session)1,708,695
Financials of Tandem Diabetes
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.02B | -$204.7M | -$59.8M |
| 2024 | $940.2M | -$96.0M | -$82.5M |
| 2023 | $747.7M | -$222.6M | -$138.8M |
| 2022 | $801.2M | -$94.6M | -$47.5M |
| 2021 | $702.8M | $15.6M | $36.5M |
Detailed financial statements for Tandem Diabetes
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tandem Diabetes
Tandem Diabetes has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Advanced Microfluidics, Amf Medica and Capillary Biomedical.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Syringe pumps, electric rotary valves, and microfluidics are manufactured. | amf.ch | Ecublens, Switzerland | 2014 | Dec 2022 | •••• | |
Insulin patch pumps for diabetes management are developed. | amf-medical.com | Grafenau, Germany | 2008 | Dec 2022 | •••• | |
Minimally invasive implants for continuous glucose monitoring are provided. | capillarybio.com | Irvine, United States | 2014 | Jul 2022 | •••• | |
Smart solutions for blood glucose monitoring are provided by Sugarmate. | sugarmate.io | New York, United States | 2016 | Jun 2020 | •••• |
Complete acquisition details for Tandem Diabetes
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Tandem Diabetes
8 dated milestones of Tandem Diabetes across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Tandem Diabetes is founded.
- Funding First funding round of $52.3M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $287.5M.
- Acquisition Acquires Sugarmate.
- Acquisition Acquires Capillary Biomedical.
- Acquisition Acquires Advanced Microfluidics.
- Acquisition Acquires Amf Medica.
Competitors of Tandem Diabetes
Tandem Diabetes has 3 listed competitors in our database, 1 of them funded. They include Modular Medical, Asante Solutions and Disetronic.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modular-medical.com | 2017 | San Diego, United States | $5.28M | 36 | Insulin pumps are developed for continuous delivery to diabetic patients. | |
| snappump.com | 2006 | Sunnyvale, United States | 27 | Insulin pump systems are developed and customized by Asante Solutions. | ||
| disetronic.com | 1984 | Indianapolis, United States | Insulin pumps and micro-dosage devices are developed for diabetes management. |
Detailed competitors of Tandem Diabetes
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Tandem Diabetes
The website of Tandem Diabetes (tandemdiabetes.com) receives about 384.6K visits a month and ranks #102,653 among all websites worldwide, #2,968 in Health Conditions and Concerns.
- Monthly visits384.6K
▲ 2.9% vs previous month
- Unique visitors127.8K
per month
- Global rank#102,653
among all websites
- Category rank#2,968
Health · Health Conditions and Concerns
- Bounce rate30%
- Pages per visit5.2
- Average visit3 min 52 sec
- DevicesDesktop 58% · Mobile 42%
Websites whose visitors overlap most with Tandem Diabetes. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| animas.com | 100% | View details | |||
medtronicdiabetes.com | medtronicdiabetes.com | 94% | #198,048 | – | |
| dexcom.com | 86% | 2.8M | #19,957 | View details | |
| libreview.com | 83% | #50,343 | View details | ||
| omnipod.com | 78% | #42,515 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Tandem Diabetes
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Diabetes
3 companies that operate in the same segment as Tandem Diabetes (Diabetes) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Small molecule drugs for various therapeutic areas are developed. | 1995 | United States | USD 165 M | USD 49.8 M | 103 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tandem Diabetes
Complete news archive for Tandem Diabetes
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tandem Diabetes
Tandem Diabetes was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Tandem Diabetes is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Tandem Diabetes is a funded company, having raised a total of $100.73M across 6 funding rounds to date. The company's 1st funding round was a Series C of $52.34M, raised on Jan 2010.
Tandem Diabetes has 2,650 employees.
Annual revenue of Tandem Diabetes is $1.02B as on Dec 31, 2025.
Tandem Diabetes is a developer of devices for continuous glucose monitoring and manual insulin delivery. It develops insulin pumps other products and services that bring innovation, convenience style to diabetes management. The first product, the t: slim Insulin Pump, features a sleek, modern design, intuitive touch-screen interface, and a rechargeable lithium-polymer battery. The company claims that this makes them closer to producing a fully automated closed-loop automated insulin delivery device that will not require human intervention to release insulin.
Tandem Diabetes's top competitors include Modular Medical, Asante Solutions and Disetronic.
Yes, Tandem Diabetes is publicly traded on NASDAQ under the ticker symbol TNDM.
Tandem Diabetes has made 4 acquisitions, including Advanced Microfluidics, Amf Medica, and Capillary Biomedical.
Tandem Diabetes has 1 investor. Key investors include CRG.
Yes. Tandem Diabetes publishes Tandem t:slim® mobile app and 1 more app, with over 100,000 downloads.
The website of Tandem Diabetes receives about 385 thousand visits a month and ranks #102,653 among all websites worldwide.